SUPN
Supernus Pharmaceuticals, Inc.
Platform & Compounding FCF
C
54.5 / 100 composite
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
-
5yr Avg ROIC
3.1%
-
Operating Margin Trend
-3.45 pp/yr
-
5yr Avg ROE
2.8%
-
5yr Share-Count CAGR
0.9%
-
5yr Revenue CAGR
5.5%
-
5yr EPS CAGR
10.4%
-
Revenue-Growth Years (5)
4/5
-
5yr FCF Margin
17.9%
-
5yr FCF/NI Conversion
22.64x
-
Net Debt / EBITDA
-6.29x
-
Interest Coverage (EBIT/Int)
30.00x
-
Altman Z-Score
5.13
Stability
Weight: 5%
D+
40
-
EPS Volatility (σ/μ)
0.60
-
Piotroski F-Score
3
-
Negative-Revenue Years (5)
1/5
2 of 2 gurus held; 2 trimmed.
- Holders
- 2
- Avg Δ position
-
-26.9%
- New buys
- 0
- Full exits
- 0